$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018
[Report Updated: 20-11-2018]

Published by Global Markets Direct: 20 Nov 2018 | 227557 | In Stock
Related Topics: Arthritis , Breast Cancer , Cancer , Dermatology , Diabetes , Immunology , Leukemia , Lupus , Ophthalmology , Respiratory

Introduction

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018

Summary

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Cytopenia, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Kidney Transplant Rejection, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyalgia Rheumatica (PMR), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.

The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

- The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects

- The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development

    BioAtla LLC

    Bristol-Myers Squibb Co

    Cue Biopharma Inc

    MedImmune LLC

    Momenta Pharmaceuticals Inc

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles

    abatacept - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    abatacept biosimilar - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    abatacept biosimilar - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    abatacept biosimilar - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CUE-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KN-019 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MEDI-5265 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products

    T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones

    Featured News & Press Releases

    Oct 17, 2018: Bristol-Myers Squibb to showcase immunoscience research and biomarker-guided treatment approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

    Jun 13, 2018: Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

    Feb 23, 2018: Orencia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan

    Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

    Nov 13, 2017: Bristol-Myers Squibb’s Orencia Rejects For Use Within NHS Scotland

    Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

    Nov 01, 2017: Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)

    Jul 26, 2017: Bristol-Myers Squibb’s ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis

    Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults

    Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

    Jun 08, 2017: Bristol-Myers Squibb Announces Availability of New ORENCIA (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis

    Mar 30, 2017: Supplemental Application of Orencia (Abatacept) Intravenous Injection 250 mg a Selective T-cell Co-stimulation Modulator for Treatment of Juvenile Idiopathic Arthritis for a Partial Change in Approved Items of Manufacturing and Marketing Approval

    Mar 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland

    Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

    Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

227557 | GMDHC1799TDB

Number of Pages

79

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - P...
22 Aug 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - P...
22 Aug 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Review, H1 2017
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin...
20 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2017
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD8...
13 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2017
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD8...
13 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017Summar...
30 May 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist -Pipeline Insights, 2017
DelveInsight’s, “Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist-Pipeline Insights, 2017...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016
Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL...
28 Dec 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Transplant Diagnostics Market by Molecular and Non-Molecular Assay Technology (Serological assay, Mixed Lymphocyte Culture, PCR Based, Sequencing Based), End-User (Hospitals and transplant centers, Research laboratories and academic institutes, Commercial Service Providers) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
Transplant diagnostics are tests that are performed pre and post-transplant procedures to check the ...
16 Sep 2016 by Allied Market Research USD $4,565 (normally
USD $5,371)
More Info
SAVE 15% today! Transplant Diagnostics Market by Molecular and Non-Molecular Assay Technology (Serological assay, Mixed Lymphocyte Culture, PCR Based, Sequencing Based), End-User (Hospitals and transplant centers, Research laboratories and academic institutes, Commercial Service Providers) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
Transplant diagnostics are tests that are performed pre and post-transplant procedures to check the ...
01 Sep 2016 by Allied Market Research USD $4,565 (normally
USD $5,371)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...